Observational studyBMJ paediatrics open2026
Association between perfluoroalkyl and polyfluoroalkyl substances and response to the COVID-19 vaccine in a paediatric prospective observational cohort in Arizona.
Observational study in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious research has shown a significant association between increased serum perfluoroalkyl and polyfluoroalkyl substances (PFAS) concentration and reduced antibody response to vaccinations in children, but this association has not yet been studied for COVID-19 vaccinations. We explored this relationship using data from the Arizona Healthcare, Emergency Response and Other Essential Workers Surveillance (AZ-HEROES) Kids study, a prospective cohort that began recruiting participants in July 2021 and followed through April 2023.
methodsAZ-HEROES Kids participants aged 6 months to 17 years were eligible for this study if they received a full primary mRNA COVID-19 BNT-162b2 (Pfizer-BioNTech) vaccine series, voluntarily submitted a blood specimen 14-60 days following the second vaccine dose and had no evidence of SARS-CoV-2 infection prior to vaccination. 13 PFAS chemicals were measured in serum samples, including branched and linear isomers of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid. A semi-quantitative ELISA was used to measure antibody binding to the SARS-CoV-2 spike protein receptor binding domain (RBD) and S2 subunit domain (S2). An area under the serial dilution curve (AUC) was calculated for RBD and S2. Regression models were fit for each PFAS chemical to assess the relationship between antibody binding (RBD and S2 AUC) and serum PFAS concentration with adjustments for age, sex, geographic region in Arizona and presence of chronic conditions.
resultsThe final sample included 120 individuals between 1 and 16 years old. An SD increase in total log-PFOS concentration was significantly associated with a 5.0% decrease in RBD AUC (95% CI -8.1% to -1.8%). The linear and branched isomers of PFOS were also significantly associated with a 4.8% (-7.9% to -1.6%) and 4.9% (-8.0% to -1.7%) decrease in RBD AUC, respectively.
conclusionsThis study contributes to the growing evidence of the negative effects of PFAS exposure on humoral response to vaccination in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.